by John Conrad | Dec 18, 2024 | iBIO in the News
iBIO President & CEO John Conrad recently had the pleasure of chatting with Kyle LaHucik to discuss the exciting developments in our biotech ecosystem. Many of you may have already seen his excellent article published yesterday in Endpoints News, which provides a...
by John Conrad | Jul 29, 2024 | iBIO in the News
GEN Releases 2024 Top Biopharma Clusters: Chicago Climbs to 9th Place Genetic Engineering & Biotechnology News (GEN) has unveiled its annual list of top biopharma clusters for 2024, with Chicago making a notable ascent in the rankings. The Windy City has moved up...
by John Conrad | Jul 25, 2024 | iBIO in the News
Heart failure tech developer Endotronix is being acquired by Edwards Lifesciences a month after receiving regulatory approval for its implantable pulmonary artery sensor. Irvine, Calif.-based Edwards said in a press release it was exercising its option to acquire...
by John Conrad | Jan 5, 2024 | iBIO in the News
On January 3rd iBIO president & CEO, John Conrad, joined his biosciences colleagues from across the country to ring the closing bell at the New York Stock Exchange (NYSE). And to talk about the industry in 2024 and the amazing growth of our life sciences industry...
by John Conrad | Jun 6, 2023 | iBIO in the News
Today, the Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released a new report on the best practices in state bioscience economic development measures, “The U.S. Biosciences Industry in the...
by John Conrad | Mar 16, 2023 | iBIO in the News
PCI Pharma Services, a Philadelphia contract drug manufacturer, is investing $50 million into a new manufacturing facility in Rockford that’s expected to create about 250 jobs. The 200,000-square-foot site will enhance the company’s ability to create a...
